- Home
- BCYC vs AKBA Comparison
BCYC vs AKBA Comparison
Compare BCYC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCYC
- AKBA
- Stock Information
- Founded
- BCYC 2009
- AKBA 2007
- Country
- BCYC United Kingdom
- AKBA United States
- Employees
- BCYC N/A
- AKBA N/A
- Industry
- BCYC Biotechnology: Pharmaceutical Preparations
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- BCYC Health Care
- AKBA Health Care
- Exchange
- BCYC Nasdaq
- AKBA Nasdaq
- Market Cap
- BCYC 581.7M
- AKBA 559.0M
- IPO Year
- BCYC 2019
- AKBA 2014
- Fundamental
- Price
- BCYC $8.34
- AKBA $2.55
- Analyst Decision
- BCYC Buy
- AKBA Strong Buy
- Analyst Count
- BCYC 10
- AKBA 4
- Target Price
- BCYC $25.00
- AKBA $6.63
- AVG Volume (30 Days)
- BCYC 401.9K
- AKBA 3.7M
- Earning Date
- BCYC 05-01-2025
- AKBA 05-08-2025
- Dividend Yield
- BCYC N/A
- AKBA N/A
- EPS Growth
- BCYC N/A
- AKBA N/A
- EPS
- BCYC N/A
- AKBA N/A
- Revenue
- BCYC $25,722,000.00
- AKBA $184,909,000.00
- Revenue This Year
- BCYC N/A
- AKBA $22.50
- Revenue Next Year
- BCYC $0.27
- AKBA $43.23
- P/E Ratio
- BCYC N/A
- AKBA N/A
- Revenue Growth
- BCYC N/A
- AKBA N/A
- 52 Week Low
- BCYC $6.10
- AKBA $0.80
- 52 Week High
- BCYC $28.67
- AKBA $2.89
- Technical
- Relative Strength Index (RSI)
- BCYC 49.88
- AKBA 65.48
- Support Level
- BCYC $7.95
- AKBA $2.25
- Resistance Level
- BCYC $9.55
- AKBA $2.90
- Average True Range (ATR)
- BCYC 0.72
- AKBA 0.14
- MACD
- BCYC 0.05
- AKBA 0.03
- Stochastic Oscillator
- BCYC 43.98
- AKBA 58.33
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.